| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
310,240,000 |
| Market
Cap: |
7.35(B) |
| Last
Volume: |
1,560,796 |
Avg
Vol: |
2,440,044 |
| 52
Week Range: |
$18.17 - $24.13 |
|
| Level
I Sector: |
Industrials |
| Level
II Sector: |
Diversified Services |
| Level
III Sector: |
Research Services |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : 14.9 |
| Insider 6 Months : 16.6 |
| Insider 3/6 Months : 32 |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Exelixis is an oncology-focused biotechnology company that engages in the discovery, development and commercialization of new medicines for cancers. Co.'s products include: CABOMETYX® (cabozantinib) tablets approved for renal cell carcinoma, and for previously treated hepatocellular carcinoma; and COMETRIQ® (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer. The other products are: COTELLIC® (cobimetinib), an inhibitor of MEK approved as part of a combination regimen to treat forms of melanoma; and MINNEBRO® (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved for the treatment of hypertension in Japan.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
190,000 |
310,409 |
310,409 |
310,409 |
| Total Buy Value |
$3,932,734 |
$6,534,772 |
$6,534,772 |
$6,534,772 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
66,225 |
325,783 |
532,046 |
1,028,448 |
| Total Sell Value |
$1,469,691 |
$7,234,582 |
$11,431,100 |
$20,278,991 |
| Total People Sold |
2 |
4 |
5 |
11 |
| Total Sell Transactions |
2 |
8 |
12 |
26 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Garber Alan M |
Director |
– • – |
2024-03-21 |
4 |
AS |
$24.01 |
$461,112 |
D/D |
(19,205) |
35,703 |
|
-6% |
|
| Garber Alan M |
Director |
– • – |
2024-03-21 |
4 |
OE |
$19.57 |
$459,719 |
D/D |
23,491 |
54,908 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2024-02-23 |
4 |
S |
$21.45 |
$1,008,579 |
D/D |
(47,020) |
384,866 |
|
-9% |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
63,350 |
431,886 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
241,670 |
1,038,327 |
|
- |
|
| Peterson Amy C. |
EVP Prod Dev & Med Aff & CMO |
• – – |
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
82,121 |
322,121 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
82,121 |
751,990 |
|
- |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
63,350 |
655,052 |
|
- |
|
| Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2024-02-23 |
4 |
A |
$0.00 |
$0 |
D/D |
63,350 |
542,381 |
|
- |
|
| Caligan Partners Lp |
See Remarks |
– • – |
2024-02-21 |
4 |
B |
$20.70 |
$3,932,734 |
I/I |
190,000 |
1,100,730 |
2.1 |
14% |
|
| Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2024-02-15 |
4 |
D |
$20.39 |
$216,746 |
D/D |
(10,630) |
479,031 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2024-01-11 |
4 |
D |
$22.86 |
$311,193 |
D/D |
(13,613) |
368,536 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2024-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
74,462 |
382,149 |
|
- |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2024-01-11 |
4 |
D |
$22.86 |
$298,574 |
D/D |
(13,061) |
591,702 |
|
- |
|
| Hessekiel Jeffrey |
EVP, General Counsel & Sec |
• – – |
2024-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
71,418 |
604,763 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2024-01-11 |
4 |
D |
$22.86 |
$499,765 |
D/D |
(21,862) |
669,869 |
|
- |
|
| Senner Christopher J. |
EVP and CFO |
• – – |
2024-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
80,186 |
691,731 |
|
- |
|
| Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2024-01-11 |
4 |
D |
$22.86 |
$265,313 |
D/D |
(11,606) |
489,661 |
|
- |
|
| Aftab Dana |
CSO/EVP Disc & Trans Research |
• – – |
2024-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
63,224 |
501,267 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2024-01-11 |
4 |
D |
$22.86 |
$1,456,571 |
D/D |
(63,717) |
796,657 |
|
- |
|
| Morrissey Michael M |
President and CEO |
• • – |
2024-01-11 |
4 |
A |
$0.00 |
$0 |
D/D |
250,374 |
860,374 |
|
- |
|
| Beckerle Mary C |
Director |
– • – |
2024-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
15,424 |
15,424 |
|
- |
|
| Eckhardt Sue Gail |
Director |
– • – |
2024-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
15,424 |
15,424 |
|
- |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2023-12-14 |
4 |
AS |
$23.35 |
$1,167,500 |
D/D |
(50,000) |
307,687 |
|
-3% |
|
| Haley Patrick J. |
EVP, Commercial |
• – – |
2023-12-14 |
4 |
OE |
$16.29 |
$814,500 |
D/D |
50,000 |
357,687 |
|
- |
|
1414 Records found
|
|
Page 1 of 57 |
|
|
0.17 (0.72%) 
